143P Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A single-arm phase II trial

Immunotherapy and BACE are important therapy for NSCLC. This trial is designed to determine the efficacy safety of immunotherapy with tislelizumab in addition stage III-IV NSCLC patients (pts) who failed, refused or ineligible receive standard treatments. enrolled pts without EGFR, ALK ROS1 aberrations have refused, assessed conventional treatments (surgery, chemoradiotherapy, chemotherapy). Pts were treated as induction during which was performed on first day given 3-5 days later, then administered at 200mg Q3W maintenance therapy. Primary endpoint progression-free survival (PFS), secondary endpoints included objective response rate (ORR), disease control (DCR), overall (OS) safety, etc. Herein, treatment 6 weeks reported. 30 24 (80%) males a median age 65.1y; 21 (70%) squamous, 9 (30%) adenocarcinomas; 4 (13%) IIIA, 11 (37%) IIIB, 15 (50%) IV; 8 (27%) ECOG score 0, 17 (57%) 1, 5(17%) 2. Among pts, 5 (17%) had bronchial stenosis, 2 (7%) superior vena cava syndrome, pneumonia, pulmonary heart disease, hemoptysis. The ORR DCR 66.7% 83.3% respectively per RECIST1.1, (6.7%) achieved complete (CR), 18 (60.0%) (16.7%) got partial (PR) stable (SD). main TEAEs related mainly include nausea (20.0%, 6/30), fever (16.7%, 5/30), hemoglobin decrease (6.7%, 2/30), leukopenia (10.0%, 3/30) thrombocytopenia 2/30). fatigue 2/30)，rash cough 3/30). Grade≥3 AEs not observed. Tislelizumab combined advanced appears be safe feasible, comorbidities can alleviated after treatment. Compared previous studies BACE, may improve DCR.